| Legal status | Investigational |
|---|---|
| Synonyms | Hemay005 |
| Cas number | 1255909-03-5 |
| Unii | 4QX9BK9E7P |
| Pubchem | 137355584 |
| Chembl | 5095240 |
| Chemspiderid | 115010424 |
| Iupac name | N-[5-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4,6-dioxothieno[3,4-c]pyrrol-3-yl]acetamide |
| Stdinchi | 1S/C20H22N2O7S2/c1-5-29-16-8-12(6-7-15(16)28-3)14(10-31(4,26)27)22-19(24)13-9-30-18(21-11(2)23)17(13)20(22)25/h6-9,14H,5,10H2,1-4H3,(H,21,23)/t14-/m1/s1 |
| Stdinchikey | PRSNGWLHNWGOKD-CQSZACIVSA-N |
| Smiles | CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=CSC(=C3C2=O)NC(=O)C)OC |
| C | 20 |
| H | 22 |
| N | 2 |
| O | 7 |
| S | 2 |
Mufemilast (Hemay005) is a small-molecule inhibitor of phosphodiesterase 4. It is developed by Hemay Pharmaceutical for psoriasis.[1][2][3]
References
- ^ Liu, Xuemei; Chen, Rui; Zeng, Guanghuai; Gao, Ying; Liu, Xiuping; Zhang, Donglei; Hu, Pei; Wang, Hongyun; Jiang, Ji (1 June 2018). "Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MS/MS and its application to a PK study". Bioanalysis. 10 (11): 863–875. doi:10.4155/bio-2018-0004. ISSN 1757-6199. PMID 29863892. S2CID 46929693
- ^ Tomar, Yashika; Gorantla, Srividya; Singhvi, Gautam (February 2023). "Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches". Drug Discovery Today. 28 (2). doi:10.1016/j.drudis.2022.103465. PMID 36481585. S2CID 254304811
- ^ Claudia, Cervantes-Durán; María-Elena, Velázquez-Hernández; Josué, Valentín-Escalera; María-Carmen, Bartolomé-Camacho; Alain-Raimundo, Rodríguez-Orozco; Martha-Estrella, García-Pérez (November 2020). "Small molecules under development for psoriasis: on the road to the individualized therapies". Archives of Dermatological Research. 312 (9): 611–627. doi:10.1007/s00403-020-02056-3. PMID 32172339. S2CID 212706837